PATENT CLAIM ANALYSIS

Application Number: 16222040
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["514", "108000"]

Abstract:
Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.

Claim (Index 14):
The method of  claim 8 , wherein the neridronic acid is administered in a dosage form providing controlled release or sustained release, or wherein the neridronic acid is administered by a delivery device.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 98.0
- Lexical Diversity: 1.26667
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16110869', '15710759', '15820305', '15647140', '15963878']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8566067747396614
- 35 USC 102 Novelty (BERT): 0.6046175165131784
- Combined Prediction Score: 0.8314078489170131
- Mean Citation Score: 624.87252
- Max Citation Score: 650.9571
- Similarity Product: 451.98737030845285

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test